Blood Cancer Information

In this section you will find disease specific information on the main types of blood cancers and allied blood disorders.

Leukaemia

Leukaemia is a cancer which starts in blood-forming tissue, usually the bone marrow. It leads to the over-production of abnormal white blood cells, the part of the immune system which defends the body against infection.

Signs and symptoms of leukaemia

Leukaemia can be hard to spot because the signs and symptoms are common to other unrelated illnesses. Knowing what to look out for could help you make the decision to visit your GP sooner for a blood test.

Leukaemia Myths

There are many myths about leukaemia. Get yourself clued up with the following guide

Lymphoma

Lymphoma is cancer that starts in the lymph glands or other organs of the lymphatic system. The lymphatic system is a network of fine vessels, glands and channels which occur throughout the body.

Myeloma

Myeloma, also known as multiple myeloma, is a cancer of the bone marrow which affects the plasma cells, a type of blood cell.

Aplastic Anaemia

Aplastic anaemia (AA) is a rare condition in which the bone marrow fails produce all three major types of blood cell. It is not a form of cancer.

Myeloproliferative neoplasms (MPN)

Myeloproliferative neoplasms (MPNs) are slow-growing blood cancers that develop when cells in your bone marrow grow out of control and make too many blood cells. There are different types of MPN depending on which type of blood cell is being over-produced.

Myelodysplastic syndromes (MDS)

Myelodysplastic syndromes (MDS) are diseases of the bone marrow. MDS is characterised by abnormal, immature blood cells that do not work properly. MDS is a type of cancer, but it is sometimes also called ‘bone marrow failure’. Here, we cover what MDS is, how it’s diagnosed, and what treatment you might have.

Left to #WatchWaitWorry resources

Support our campaign and download our #WatchWaitWorry graphics below.

Read More

Take a Moment to Catch Up

View our latest news and blog articles

November 11th

Additional treatment for AML patients now available in Scotland

Leukaemia Care is pleased to announce that newly diagnosed acute myeloid leukaemia (AML) patients with a FLT3 mutation now have access to quizartinib, in combination with chemotherapy, thanks to a decision made by the Scottish Medicines Consortium (SMC) today. ...

October 31st

Leukaemia Care’s response to the 2024 Autumn Budget

"We welcome the increase in the NHS budget. However..." - Colin Dyer, Chief Executive at Leukaemia Care shares the charity's response....

October 22nd

NEW NHS treatment option for myelofibrosis patients

Certain patients with myelofibrosis will have access to fedratinib to treat myelofibrosis, thanks to a decision made by the National Institute for Health and Care Excellence (NICE). ...